A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

Completed · Phase 2 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.

Key facts

Study ID

NCT04881760

Run by

Eli Lilly and Company

People needed

338

Starts

2021-05-20

Expected to finish

2022-11-22

Last updated by the study team

2023-09-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have a Body Mass Index (BMI) ) ≥30 and ≤50 kilograms per square meter (kg/m²), or ≥27 kg/m² and <30 kg/m², with at least one of the following comorbidities: hypertension, dyslipidemia, cardiovascular disease
• Participants must be willing to learn how to self-inject study drug or receive an injection from a trained individual if visually impaired or with physical limitations, and follow study procedures for the duration of the study, including, but not limited to, follow lifestyle advice (for example, dietary changes and physical activity plan), maintain a study drug administration log, and complete required questionnaires

You may not qualify if…

• Participants must not have type 1 or type 2 diabetes mellitus
• Participants must not have had an increase or decrease in body weight > more than 5 kg (11 pounds) within the past 3 months
• Participants must not have had surgery for obesity or plan to have such surgery during the study
• Participants must not be using medications that promote weight loss or cause weight gain
• Participants must not drink excessive amounts of alcohol (more than 14 units a week for women or more than 21 units a week for men)
• Participants must not have used marijuana within the last 3 months.
• Participants must not have heart attack, stroke, or hospitalization for congestive heart failure in the past 3 months
• Participants must not have active cancer within the last 5 years
• Participants must not have uncontrolled high blood pressure
• Participants must not have liver disease other than non-alcoholic fatty liver disease
• Participants must not have renal impairment with estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
• Participants must not have a history of acute or chronic pancreatitis symptomatic gallbladder disease or documented human immunodeficiency virus infection
• Participants must not have a major problem with depression or other mental illness within the last 2 years
• Participants must not have family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma (family is defined as a first degree relative)
• Female participants must not be pregnant, breast-feeding, or intend to become pregnant or of childbearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice)

Where it is running

• Perseverance Research Center — Scottsdale, Arizona, United States
• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• Valley Research — Fresno, California, United States
• Velocity Clinical Research, Huntington Park — Huntington Park, California, United States
• Velocity Clinical Research, Huntington Park — Los Angeles, California, United States
• Southern California Dermatology, Inc. — Santa Ana, California, United States
• Coastal Metabolic Research Centre — Ventura, California, United States
• Diablo Clinical Research, Inc. — Walnut Creek, California, United States
• East Coast Institute for Research, LLC — Jacksonville, Florida, United States
• Suncoast Clinical Research, Inc. — New Port Richey, Florida, United States
• Encore Medical Research - Weston — Weston, Florida, United States
• Springfield Diabetes & Endocrine Center — Springfield, Illinois, United States
• Cotton O'Neil Diabetes and Endocrinology Center — Topeka, Kansas, United States
• Tandem Clinical Research,LLC — Marrero, Louisiana, United States
• StudyMetrix Research — City of Saint Peters, Missouri, United States
• Amici Clinical Research LLC — Raritan, New Jersey, United States
• Intend Research, LLC — Norman, Oklahoma, United States
• Allegheny Endocrinology Associates — Pittsburgh, Pennsylvania, United States
• New Phase Research and Development — Knoxville, Tennessee, United States
• Texas Diabetes & Endocrinology, P.A. — Austin, Texas, United States
• Dallas Diabetes Research Center — Dallas, Texas, United States
• Juno Research — Houston, Texas, United States
• Endocrine Ips, Pllc — Houston, Texas, United States
• Southern Endocrinology Associates — Mesquite, Texas, United States
• Rainier Clinical Research Center — Renton, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.